253 related articles for article (PubMed ID: 11856485)
1. Bromocriptine reverses P-glycoprotein-mediated multidrug resistance in tumor cells.
Shiraki N; Okamura K; Tokunaga J; Ohmura T; Yasuda K; Kawaguchi T; Hamada A; Nakano M
Jpn J Cancer Res; 2002 Feb; 93(2):209-15. PubMed ID: 11856485
[TBL] [Abstract][Full Text] [Related]
2. Increase in doxorubicin cytotoxicity by inhibition of P-glycoprotein activity with lomerizine.
Shiraki N; Hamada A; Ohmura T; Tokunaga J; Oyama N; Nakano M
Biol Pharm Bull; 2001 May; 24(5):555-7. PubMed ID: 11379779
[TBL] [Abstract][Full Text] [Related]
3. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
[TBL] [Abstract][Full Text] [Related]
4. Increase in doxorubicin cytotoxicity by carvedilol inhibition of P-glycoprotein activity.
Jonsson O; Behnam-Motlagh P; Persson M; Henriksson R; Grankvist K
Biochem Pharmacol; 1999 Dec; 58(11):1801-6. PubMed ID: 10571255
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.
Jovelet C; Bénard J; Forestier F; Farinotti R; Bidart JM; Gil S
Eur J Pharm Sci; 2012 Aug; 46(5):484-91. PubMed ID: 22484209
[TBL] [Abstract][Full Text] [Related]
6. A novel flavonoid from Fissistigma cupreonitens, 5‑hydroxy‑7,8‑dimethoxyflavanone, competitively inhibited the efflux function of human P-glycoprotein and reversed cancer multi-drug resistance.
Teng YN; Lin KI; Lin YC; Thang TD; Lan YH; Hung CC
Phytomedicine; 2021 May; 85():153528. PubMed ID: 33735724
[TBL] [Abstract][Full Text] [Related]
7. Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6.
Zhu HJ; Wang JS; Guo QL; Jiang Y; Liu GQ
Biol Pharm Bull; 2005 Oct; 28(10):1974-8. PubMed ID: 16204958
[TBL] [Abstract][Full Text] [Related]
8. Bromocriptine modulates P-glycoprotein function.
Orlowski S; Valente D; Garrigos M; Ezan E
Biochem Biophys Res Commun; 1998 Mar; 244(2):481-8. PubMed ID: 9514944
[TBL] [Abstract][Full Text] [Related]
9. Specificity of doxorubicin versus rhodamine-123 in assessing P-glycoprotein functionality in the LLC-PK1, LLC-PK1:MDR1 and Caco-2 cell lines.
van der Sandt IC; Blom-Roosemalen MC; de Boer AG; Breimer DD
Eur J Pharm Sci; 2000 Sep; 11(3):207-14. PubMed ID: 11042226
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the P-glycoprotein- and multidrug resistance protein-mediated efflux of anthracyclines and calceinacetoxymethyl ester by PAK-104P.
Marbeuf-Gueye C; Salerno M; Quidu P; Garnier-Suillerot A
Eur J Pharmacol; 2000 Mar; 391(3):207-16. PubMed ID: 10729360
[TBL] [Abstract][Full Text] [Related]
11. Modulation of multidrug resistant in cancer cells by EGCG, tannic acid and curcumin.
Li H; Krstin S; Wink M
Phytomedicine; 2018 Nov; 50():213-222. PubMed ID: 30466981
[TBL] [Abstract][Full Text] [Related]
12. Development of novel reversal agents, imidazothiazole derivatives, targeting MDR1- and MRP-mediated multidrug resistance.
Naito S; Koike K; Ono M; Machida T; Tasaka S; Kiue A; Koga H; Kumazawa J
Oncol Res; 1998; 10(3):123-32. PubMed ID: 9700723
[TBL] [Abstract][Full Text] [Related]
13. Functional detection of MDR1/P170 and MRP/P190-mediated multidrug resistance in tumour cells by flow cytometry.
Feller N; Kuiper CM; Lankelma J; Ruhdal JK; Scheper RJ; Pinedo HM; Broxterman HJ
Br J Cancer; 1995 Sep; 72(3):543-9. PubMed ID: 7669559
[TBL] [Abstract][Full Text] [Related]
14. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR1 gene by liposomes in combination with monoclonal antibody or verapamil.
Sela S; Husain SR; Pearson JW; Longo DL; Rahman A
J Natl Cancer Inst; 1995 Jan; 87(2):123-8. PubMed ID: 7707383
[TBL] [Abstract][Full Text] [Related]
15. Reversal of P-glycoprotein mediated multidrug resistance by a newly synthesized 1,4-benzothiazipine derivative, JTV-519.
Che XF; Nakajima Y; Sumizawa T; Ikeda R; Ren XQ; Zheng CL; Mukai M; Furukawa T; Haraguchi M; Gao H; Sugimoto Y; Akiyama S
Cancer Lett; 2002 Dec; 187(1-2):111-9. PubMed ID: 12359358
[TBL] [Abstract][Full Text] [Related]
16. Cinnamophilin overcomes cancer multi-drug resistance via allosterically modulating human P-glycoprotein on both drug binding sites and ATPase binding sites.
Teng YN; Huang BH; Huang SY; Wu IT; Wu TS; Lee TE; Hung CC
Biomed Pharmacother; 2021 Dec; 144():112379. PubMed ID: 34794239
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric functional analysis of multidrug resistance by Fluo-3: a comparison with rhodamine-123.
Koizumi S; Konishi M; Ichihara T; Wada H; Matsukawa H; Goi K; Mizutani S
Eur J Cancer; 1995 Sep; 31A(10):1682-8. PubMed ID: 7488425
[TBL] [Abstract][Full Text] [Related]
18. Reversal of multidrug resistance by Marsdenia tenacissima and its main active ingredients polyoxypregnanes.
To KKW; Wu X; Yin C; Chai S; Yao S; Kadioglu O; Efferth T; Ye Y; Lin G
J Ethnopharmacol; 2017 May; 203():110-119. PubMed ID: 28363522
[TBL] [Abstract][Full Text] [Related]
19. Cellular and biochemical characterization of VX-710 as a chemosensitizer: reversal of P-glycoprotein-mediated multidrug resistance in vitro.
Germann UA; Shlyakhter D; Mason VS; Zelle RE; Duffy JP; Galullo V; Armistead DM; Saunders JO; Boger J; Harding MW
Anticancer Drugs; 1997 Feb; 8(2):125-40. PubMed ID: 9073309
[TBL] [Abstract][Full Text] [Related]
20. Reversal of multidrug resistance in human leukemia K562 by tamolarizine, a novel calcium antagonist.
Miyake N; Fujita R; Ishikawa M; Takayanagi M; Takayanagi Y; Sasaki K
Jpn J Pharmacol; 2000 Mar; 82(3):265-8. PubMed ID: 10887958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
